Key Points

- Axsome Therapeutics has started the SUMMIT Phase 3 trial of AXS-05 for smoking cessation
- The trial aims to evaluate the efficacy and safety of AXS-05 in adults
- This is a randomized, double-blind, active- and placebo-controlled, multicenter trial
- The first patient has been dosed in the trial
- AXS-05 is being studied for its potential in helping individuals quit smoking

Axsome Therapeutics, a renowned biopharmaceutical company specializing in central nervous system disorders treatment, has recently launched the SUMMIT Phase 3 trial for their latest drug, AXS-05, intended for smoking cessation. The trial, officially known as Studying NMDA and Sigma-1 in Smoking Cessation Treatment, is designed as a Phase 3 study that will involve randomizing participants. It will also be double-blind, active- and placebo-controlled, and will take place across multiple centers with the primary goal of assessing the effectiveness and safety of AXS-05 in aiding adults to quit smoking.

The first patient has already received a dosage within the SUMMIT trial, marking a significant milestone for Axsome Therapeutics as they progress through this crucial phase of research. AXS-05, the focal point of the study, is being closely monitored for its potential as a breakthrough smoking cessation treatment. The trial seeks to provide valuable insights into the drug's capabilities, furthering the understanding of its possible benefits in helping individuals overcome nicotine addiction.

With the initiation of the SUMMIT Phase 3 trial, Axsome Therapeutics is taking a proactive approach in addressing the pressing issue of smoking cessation. By delving into the efficacy and safety of AXS-05 as a viable treatment option, the company aims to contribute to the development of solutions that can make a meaningful impact on public health. The comprehensive nature of the trial, including its randomized design and the use of both active and placebo controls, underscores the rigor and thoroughness with which Axsome is approaching this critical study.

As the SUMMIT trial progresses, researchers and participants alike will eagerly await the results that will emerge from this Phase 3 investigation. The implications of a successful outcome could potentially lead to the introduction of a new, innovative smoking cessation therapy that offers hope to individuals struggling with addiction. The momentum generated by the dosing of the first patient signifies the beginning of a journey towards potentially transformative advancements in the field of smoking cessation treatment.

About AXS

AXIS Capital Holdings Ltd. engages in the provision of various insurance and reinsurance products and services. It operates through the Insurance and Reinsurance segments. The Insurance segment offers property, marine, terrorism, aviation, political risk, professional lines, liability, accident, and health insurance products. The Reinsurance segment offers non-life treaty reinsurance to insurance companies. The company was founded on December 9, 2002, and is headquartered in Pembroke, Bermuda.

For more information:

Up/Down Rally

Price Distribution

Analyst Recommendations

Earning Price Impact Analysis

Seasonality